N-(4-(imidazo[1,2-a]pyridin-2-yl)-phenyl)-2,2,2-trifluoroacetamide | 1291779-70-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-(4-(imidazo[1,2-a]pyridin-2-yl)-phenyl)-2,2,2-trifluoroacetamide
• 英文别名: N-[4-(Imidazo[1,2-a]pyridin-2-yl)-phenyl]-2,2,2-trifluoro-acetamide；2,2,2-trifluoro-N-(4-imidazo[1,2-a]pyridin-2-ylphenyl)acetamide
• CAS: 1291779-70-8
• 化学式: C₁₅H₁₀F₃N₃O
• 分子量: 305.259
• InChiKey: ISXKGVWGASMQSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  46.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(4-(imidazo[1,2-a]pyridin-2-yl)-phenyl)-2,2,2-trifluoroacetamide 在 水 、 sodium hydride 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-(indolizin-2-yl)-N-methylbenzeneamine
  参考文献：
  名称：

  Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure

  摘要：

  Based on a high-throughput screen, cyclopentanecarboxanilides were identified as a new chemotype of non-covalent inhibitors of type I fatty acid synthase (FAS). Starting from initial hits we aimed at generating a tool compound suitable for the in vivo validation of FAS as a therapeutic target. Optimisation yielded BI 99179 which is characterised by high potency, remarkably high selectivity and significant exposure (both peripheral and central) upon oral administration in rats. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.083
• 作为产物：
  描述：

  4-(咪唑并[1,2-a]吡啶-2-基)苯胺 、 三氟乙酸酐 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-(4-(imidazo[1,2-a]pyridin-2-yl)-phenyl)-2,2,2-trifluoroacetamide
  参考文献：
  名称：

  Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure

  摘要：

  Based on a high-throughput screen, cyclopentanecarboxanilides were identified as a new chemotype of non-covalent inhibitors of type I fatty acid synthase (FAS). Starting from initial hits we aimed at generating a tool compound suitable for the in vivo validation of FAS as a therapeutic target. Optimisation yielded BI 99179 which is characterised by high potency, remarkably high selectivity and significant exposure (both peripheral and central) upon oral administration in rats. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.083

文献信息

• [EN] CYCLOPENTANECARBOXAMIDE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE<br/>[FR] DÉRIVÉS DE CYCLOPENTANECARBOXAMIDE, MÉDICAMENTS CONTENANT CES COMPOSÉS ET LEUR UTILISATION
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2011048018A1

  公开（公告）日：2011-04-28

  The invention relates to cyclopentanecarboxamide derivatives of formula 1, to their use as Fatty Acid Synthase inhibitors, to methods for their therapeutic use and to pharmaceutical compositions containing them, wherein R1, R2, R3, LO, W, AR1, n are as defined in claim 1.

  这项发明涉及公式1的环戊烷羧酰胺衍生物，它们的用途是作为脂肪酸合成酶抑制剂，用于它们的治疗用途的方法，以及含有它们的药物组合物，其中R1、R2、R3、LO、W、AR1、n如权利要求1中所定义。
• Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use
  申请人：Kley Joerg

  公开号：US20130053412A1

  公开（公告）日：2013-02-28

  The invention relates to cyclopentanecarboxamide derivatives of formula 1, to their use as Fatty Acid Synthase inhibitors, to methods for their therapeutic use and to pharmaceutical compositions containing them, wherein R 1 , R 2 , R 3 , LO, W, AR 1 , n are as defined in claim 1 .

  本发明涉及公式1的环戊烷羧酰胺衍生物，以及它们作为脂肪酸合成酶抑制剂的用途，它们的治疗应用方法以及含有它们的制药组合物，其中R1，R2，R3，LO，W，AR1，n如权利要求1所定义。
• CYCLOPENTANECARBOXAMIDE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2491009B1

  公开（公告）日：2017-07-05
• US8614238B2
  申请人：——

  公开号：US8614238B2

  公开（公告）日：2013-12-24
• Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure
  作者：Jörg T. Kley、Jürgen Mack、Bradford Hamilton、Stefan Scheuerer、Norbert Redemann

  DOI：10.1016/j.bmcl.2011.07.083

  日期：2011.8

  Based on a high-throughput screen, cyclopentanecarboxanilides were identified as a new chemotype of non-covalent inhibitors of type I fatty acid synthase (FAS). Starting from initial hits we aimed at generating a tool compound suitable for the in vivo validation of FAS as a therapeutic target. Optimisation yielded BI 99179 which is characterised by high potency, remarkably high selectivity and significant exposure (both peripheral and central) upon oral administration in rats. (C) 2011 Elsevier Ltd. All rights reserved.